System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Florent Grange is an expert in Dermatology at Centre Hospitalier Universitaire de Reims (France). As of October 2026, ScienceLeadR ranks Florent Grange in the top 1% of experts worldwide for Skin Neoplasms, Melanoma and Sexually Transmitted Diseases. Florent Grange has authored 432 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 3 of them ongoing. SLR score: 1,157 (community average: 125). How the SLR is computed.

LeadR Profile

Florent Grange Centre Hospitalier Universitaire de Reims France
1 157 ScienceLeadR Reputation 1157

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Hematology - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1992 - 2026
Source: PubMed

Hôpital Robert-Debré

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 432

Citations

Citations: 18 868 1st author: 40 Last author: 89 Unique author: 9

Main journals

Ann Dermatol Venereol 153
Br J Dermatol 21
J Eur Acad Dermatol Venereol 20
Ann Oncol 19
Annales de Dermatologie et de Vénéréologie - FMC 18

Best Journals

Ann Oncol 10
J Clin Oncol 7
Lancet Oncol 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single-Arm Phase II Study.
PMID 42791653 — cells, merkel cells, somatostatin, neoplasms, therapeutics, dermatology, carcinoma, merkel cell		Cancer Med20260
Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome.
PMID 42490360 — syphilis, sezary syndrome, dermatology		Br J Dermatol20260
Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).
PMID 42372635 — melanoma, neoplasms, cohort studies, therapeutics		Eur J Cancer20260
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.
PMID 42025759 — cells, vaccines, progression-free survival, melanoma, neoplasms, drug-related side effects and adverse reactions, cancer vaccines		Ann Oncol Top journal20260
Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA.
PMID 41806521 — cells, safety, carcinoma, squamous cell, neoplasms, therapeutics		Eur J Cancer20260

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3

By phase:

Phase 2 7
Phase 3 7
N/A 6

By status:

Completed 9
Recruiting 4
Active not recruiting 3
Terminated 2
Unknown 2

By type:

Interventional 15
Observational 5

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 0
multicentric5to9 1
multicentricup10 14

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Follow up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment
NCT07606508 — skin, cells, carcinoma, squamous cell, neoadjuvant therapy, therapeutics, carcinoma, cutaneous squamous cell carcinoma		N/ARecruiting2021
Study of a Strategy Integrating Adjuvant Radiation Therapy Versus Strategy Based on Monitoring in the Treatment of Carcinomas Spinocellular With High Risk of Recurrence
NCT06692556 — radiotherapy, skin, cells, carcinoma, squamous cell, brachytherapy, neoplasms, radiotherapy, adjuvant, beds, therapeutics, nervous system, carcinoma, cutaneous squamous cell carcinoma		Phase 3Recruiting2025
Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri scar Dermatoheliosis as a Predictive Factor of Response to Anti PD 1
NCT05856565 — skin, intelligence, cicatrix, melanoma, neoplasms, algorithms, immunotherapy, photography, therapeutics, artificial intelligence		N/ARecruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS